Connor, Clark & Lunn Investment Management (CC&L)’s NovoCure NVCR Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.81M	Buy	716,539 +55,242	+8%	+$690K	0.02%	546
2025 Q4	$8.55M	Buy	661,297 +96,794	+17%	+$1.24M	0.02%	501
2025 Q3	$7.29M	Sell	564,503 -46,211	-8%	-$617K	0.02%	483
2025 Q2	$10.9M	Buy	610,714 +75,965	+14%	+$1.32M	0.04%	378
2025 Q1	$9.53M	Buy	534,749 +96,977	+22%	+$2.2M	0.04%	325
2024 Q4	$13M	Buy	437,772 +11,509	+3%	+$244K	0.06%	258
2024 Q3	$6.66M	Buy	426,263 +59,608	+16%	+$1.08M	0.03%	373
2024 Q2	$6.28M	Buy	366,655 +52,278	+17%	+$919K	0.03%	376
2024 Q1	$4.91M	Sell	314,377 -95,223	-23%	-$1.4M	0.02%	434
2023 Q4	$6.12M	Buy	409,600 +761	+0.2%	+$10.2K	0.03%	369
2023 Q3	$6.6M	Buy	408,839 +339,610	+491%	+$9.79M	0.03%	329
2023 Q2	$2.87M	Buy	69,229 +59,978	+648%	+$3.72M	0.01%	510
2023 Q1	$556K	Buy	+9,251	New	+$739K	﹤0.01%	856
2022 Q3	–	Sell	-12,750	Closed	-$886K	–	1210
2022 Q2	$886K	Buy	+12,750	New	+$960K	0.01%	648